Ed said ..."Is NEU a bit of a unicorn in this sense?" I think...

Ed said ..."Is NEU a bit of a unicorn in this sense?"

I think one of the major differentiating factors here is that our therapies are exactly that .. therapies, not cures. A patient cured with a drug is cured once, and the seller of that drug receives payment just once (across a program of treatment of course) from that patient.

As such and until better therapies for our targeted indications are developed, NEU, or whichever entity ends up with our FDA approved and patented products, will be receiving annuity income from the same patients year-in year-out.

The DCF'd numbers run from a small handful of neuro indications could well produce double hundred share values. I've said before that my assessment on entry to NEU 10 years ago was $20 from solely trofinitide/Daybue, and I'm now thinking $50+ from a takeover by middle 2024 subject to at least one unequivocally successful P2 in NNZ2591.